Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-10-12

FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)

View source ↗

Summary

FDA approves a supplemental application for Sabril (vigabatrin) submitted by Lundbeck Pharmaceuticals LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SABRIL (VIGABATRIN)

Snippet

SUPPL AP for SABRIL (VIGABATRIN)